Chargement en cours...
Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL. Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated in a pivotal phase 2 clinical trial. The hist...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3938434/ https://ncbi.nlm.nih.gov/pubmed/24586514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0089080 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|